Aridis Pharmaceuticals Inc.
| NASDAQ: ARDS | Healthcare / Biotechnology / USA |
| 5.82 | +0.1800 | +3.19% | Vol 11.40K | 1Y Perf -3.49% |
| Apr 19th, 2021 16:00 DELAYED |
| BID | 5.61 | ASK | 5.85 | ||
| Open | 5.70 | Previous Close | 5.64 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 17.20 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 195.53 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 65.35M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 20.44 | Earnings Date | 11th May 2021 |
Today's Price Range 5.555.92 | 52W Range 4.7010.18 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 9.81% | ||
| 1 Month | -17.33% | ||
| 3 Months | -19.72% | ||
| 6 Months | -24.71% | ||
| 1 Year | -3.49% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 129.09 | |||
ROE last 12 Months | 885.35 | |||
ROA (5Y Avg) | -103.81 | |||
ROA last 12 Months | -103.67 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -770.63 | |||
Return on invested Capital Q | -1 042.89 | |||
Return on invested Capital Y | -198.20 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.30 | ||||
| 15.71 | ||||
| 65.38 | ||||
| - | ||||
| -3.90 | ||||
| -2.23 | ||||
| -7.27 | ||||
| -0.77 | ||||
| 55.09M | ||||
| Forward PE | -5.27 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.50 | ||||
| 0.60 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | -2.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 226.70 | ||||
| -2 193.00 | ||||
| -1 835.50 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.00M | ||||
| 0.09 | ||||
| -13.37 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.54 | -0.59 | -9.26 |
| Q03 2020 | -0.55 | -0.65 | -18.18 |
| Q02 2020 | -0.72 | -0.47 | 34.72 |
| Q01 2020 | -0.62 | -0.73 | -17.74 |
| Q04 2019 | - | -0.63 | - |
| Q03 2019 | -0.86 | -0.87 | -1.16 |
| Q02 2019 | -1.09 | -1.03 | 5.50 |
| Q01 2019 | -0.82 | -0.99 | -20.73 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.58 | 76.13 | Positive |
| 6/2021 QR | -0.52 | 86.73 | Positive |
| 12/2021 FY | -2.30 | - | - |
| 12/2022 FY | -1.07 | - | - |
| Next Report Date | 11th May 2021 |
| Estimated EPS Next Report | -0.58 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 11.40K |
| Shares Outstanding | 11.23M |
| Trades Count | 91 |
| Dollar Volume | 239.73K |
| Avg. Volume | 30.50K |
| Avg. Weekly Volume | 12.81K |
| Avg. Monthly Volume | 31.05K |
| Avg. Quarterly Volume | 33.00K |
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock closed at 5.82 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 11.40K shares and market capitalization of 65.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Aridis Pharmaceuticals Inc. CEO is Vu Truong.
The one-year performance of Aridis Pharmaceuticals Inc. stock is -3.49%, while year-to-date (YTD) performance is -4.12%. ARDS stock has a five-year performance of %. Its 52-week range is between 4.7 and 10.18, which gives ARDS stock a 52-week price range ratio of 20.44%
Aridis Pharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 15.71, a price-to-sale (PS) ratio of 65.38, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -103.67%, a ROC of -770.63% and a ROE of 885.35%. The company’s profit margin is -%, its EBITDA margin is -2 193.00%, and its revenue ttm is $1.00 Million , which makes it $0.09 revenue per share.
Of the last four earnings reports from Aridis Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.58 for the next earnings report. Aridis Pharmaceuticals Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for Aridis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $17.2, which is +195.53% compared to the current price. The earnings rating for Aridis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aridis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aridis Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.91, ATR14 : 0.55, CCI20 : -38.89, Chaikin Money Flow : -0.45, MACD : -0.35, Money Flow Index : 51.07, ROC : -1.36, RSI : 49.83, STOCH (14,3) : 48.06, STOCH RSI : 1.00, UO : 46.05, Williams %R : -51.94), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aridis Pharmaceuticals Inc. in the last 12-months were:
Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
CEO: Vu Truong
Telephone: +1 408 385-1742
Address: 5941 Optical Court, San Jose 95138, CA, US
Number of employees: 32
